[
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: CVS Stock Jumps as Pharmacy Segment Delivers Growth",
    "summary": "The S&P 500 dropped 0.3% on Wednesday, Feb. 12, as hotter-than-expected inflation data in the January CPI report weighed on the interest rate outlook.",
    "url": "https://finnhub.io/api/news?id=117f340922c1c4dd3c42db401d2f99288dc372f3213882f6bec8a73bc222569c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739396181,
      "headline": "S&P 500 Gains and Losses Today: CVS Stock Jumps as Pharmacy Segment Delivers Growth",
      "id": 132741040,
      "image": "https://www.investopedia.com/thmb/kx3okyqVxpGOulzinzdYjjcLxU8=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1767478157-79ec5e21290e4cb99cdedb1850a89500.jpg",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The S&P 500 dropped 0.3% on Wednesday, Feb. 12, as hotter-than-expected inflation data in the January CPI report weighed on the interest rate outlook.",
      "url": "https://finnhub.io/api/news?id=117f340922c1c4dd3c42db401d2f99288dc372f3213882f6bec8a73bc222569c"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Hits Buy Zone After Obliterating Fourth-Quarter Expectations",
    "summary": "Gilead stock surged to a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat profit outlook.",
    "url": "https://finnhub.io/api/news?id=309c093567825b5bb4a32970532acfe5a1aca7bd64b1235488539b82afa97668",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739395089,
      "headline": "Gilead Hits Buy Zone After Obliterating Fourth-Quarter Expectations",
      "id": 132766595,
      "image": "https://media.zenfs.com/en/ibd.com/220b994ba82b273562061a4d57daf68d",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead stock surged to a buy zone Wednesday after the company obliterated fourth-quarter forecasts and issued an upbeat profit outlook.",
      "url": "https://finnhub.io/api/news?id=309c093567825b5bb4a32970532acfe5a1aca7bd64b1235488539b82afa97668"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
    "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739392800,
      "headline": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
      "id": 132698753,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205585/image_1322205585.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=10b10afe2a805029d7ce2f9c8b1ec10ce14300270ce9d50ee7971586c5474449"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences (GILD) Stock Is Trading Up Today",
    "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue, EPS, and adjusted operating income estimates. Revenue grew 6%, driven by a 16% increase in HIV product sales and supported by strength in oncology and liver disease products. The momentum is expected to continue into the next year, as full-year EPS guidance surpassed Wall Street estimates, while sales gu",
    "url": "https://finnhub.io/api/news?id=f35d5c1dbb974688849a745afa4f35fbc1bb78d3a699d25ab8bc19be5963a918",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739386174,
      "headline": "Why Gilead Sciences (GILD) Stock Is Trading Up Today",
      "id": 132766596,
      "image": "https://s.yimg.com/ny/api/res/1.2/lyWUZYMtpQ1Jlvi5PE5Bbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue, EPS, and adjusted operating income estimates. Revenue grew 6%, driven by a 16% increase in HIV product sales and supported by strength in oncology and liver disease products. The momentum is expected to continue into the next year, as full-year EPS guidance surpassed Wall Street estimates, while sales gu",
      "url": "https://finnhub.io/api/news?id=f35d5c1dbb974688849a745afa4f35fbc1bb78d3a699d25ab8bc19be5963a918"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences Stock Is Jumping Today",
    "summary": "Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday.  Gilead reported fourth-quarter revenue of $7.6 billion, up 6% year over year.  It posted earnings per share (EPS) of $1.42 based on generally accepted accounting principles (GAAP), reflecting a year-over-year increase of roughly 25%.",
    "url": "https://finnhub.io/api/news?id=96ca7530c2554863979037c8dfe7901e824356f6c9af528a0b786bbe33128c96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739380867,
      "headline": "Why Gilead Sciences Stock Is Jumping Today",
      "id": 132766597,
      "image": "https://g.foolcdn.com/editorial/images/807456/scientists-happy.jpg",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday.  Gilead reported fourth-quarter revenue of $7.6 billion, up 6% year over year.  It posted earnings per share (EPS) of $1.42 based on generally accepted accounting principles (GAAP), reflecting a year-over-year increase of roughly 25%.",
      "url": "https://finnhub.io/api/news?id=96ca7530c2554863979037c8dfe7901e824356f6c9af528a0b786bbe33128c96"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3ed45f892c4e494dfe3f6148b89315a98f8936cb5d0498323f8b71e896eb1c2b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739377800,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 132705327,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3ed45f892c4e494dfe3f6148b89315a98f8936cb5d0498323f8b71e896eb1c2b"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=d08622a44b23d83e12d434b950378d96a90448cd16991371a605b9da466980d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739371211,
      "headline": "Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?",
      "id": 132766598,
      "image": "https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=d08622a44b23d83e12d434b950378d96a90448cd16991371a605b9da466980d5"
    }
  },
  {
    "ts": null,
    "headline": "GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance",
    "summary": "Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up.",
    "url": "https://finnhub.io/api/news?id=054675635c42796bcf7b8d52ff9186e3456eba9c6b18e3a8388131113cc46489",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739366760,
      "headline": "GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance",
      "id": 132766599,
      "image": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up.",
      "url": "https://finnhub.io/api/news?id=054675635c42796bcf7b8d52ff9186e3456eba9c6b18e3a8388131113cc46489"
    }
  },
  {
    "ts": null,
    "headline": "Q4 2024 Gilead Sciences Inc Earnings Call",
    "summary": "Q4 2024 Gilead Sciences Inc Earnings Call",
    "url": "https://finnhub.io/api/news?id=83383a17dc20d42822cd29c984ab9b300b3463fbc72492611028370b04dce21a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739364645,
      "headline": "Q4 2024 Gilead Sciences Inc Earnings Call",
      "id": 132766600,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Q4 2024 Gilead Sciences Inc Earnings Call",
      "url": "https://finnhub.io/api/news?id=83383a17dc20d42822cd29c984ab9b300b3463fbc72492611028370b04dce21a"
    }
  },
  {
    "ts": null,
    "headline": "Medicare Reform to Flatten Gilead's Booming HIV Sales",
    "summary": "Medicare Reform to Flatten Gilead's Booming HIV Sales",
    "url": "https://finnhub.io/api/news?id=a4448a6fdd4a85cbf3ad868921b127b13a10665dd951d59ac84e15b4f9ff7ebb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739362380,
      "headline": "Medicare Reform to Flatten Gilead's Booming HIV Sales",
      "id": 132684217,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Medicare Reform to Flatten Gilead's Booming HIV Sales",
      "url": "https://finnhub.io/api/news?id=a4448a6fdd4a85cbf3ad868921b127b13a10665dd951d59ac84e15b4f9ff7ebb"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Intel, Alibaba, Super Micro, Lyft and Barratt Redrow",
    "summary": "The latest investor updates on stocks that are trending on Wednesday.",
    "url": "https://finnhub.io/api/news?id=c3de888da878fbb24e22bfe39a3b4dd5177652b2b2225c78932f02926a7d0847",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739357172,
      "headline": "Trending tickers: Intel, Alibaba, Super Micro, Lyft and Barratt Redrow",
      "id": 132766601,
      "image": "https://s.yimg.com/ny/api/res/1.2/NFzxUv2TMOR0Ic9GQEXNbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/c152a940-9c88-11ef-b7ff-54d6c513abc1",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Wednesday.",
      "url": "https://finnhub.io/api/news?id=c3de888da878fbb24e22bfe39a3b4dd5177652b2b2225c78932f02926a7d0847"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Tops Buy Zone After Obliterating Fourth-Quarter Expectations",
    "summary": "Gilead Tops Buy Zone After Obliterating Fourth-Quarter Expectations",
    "url": "https://finnhub.io/api/news?id=afef3958cc57f29626ccf4231b9996c106f7456685eb65ed876548610c6e67fa",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739357049,
      "headline": "Gilead Tops Buy Zone After Obliterating Fourth-Quarter Expectations",
      "id": 132684197,
      "image": "",
      "related": "GILD",
      "source": "DowJones",
      "summary": "Gilead Tops Buy Zone After Obliterating Fourth-Quarter Expectations",
      "url": "https://finnhub.io/api/news?id=afef3958cc57f29626ccf4231b9996c106f7456685eb65ed876548610c6e67fa"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences: Strong Q4 Results And Huge Progress In HIV",
    "summary": "Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.",
    "url": "https://finnhub.io/api/news?id=53b543ed9c37a15d01fc7679d897fef9d9f0b1bfd8e1388f231e78091f5ad895",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739348729,
      "headline": "Gilead Sciences: Strong Q4 Results And Huge Progress In HIV",
      "id": 132679415,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1209171665/image_1209171665.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.",
      "url": "https://finnhub.io/api/news?id=53b543ed9c37a15d01fc7679d897fef9d9f0b1bfd8e1388f231e78091f5ad895"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...",
    "summary": "Gilead Sciences Inc (GILD) reports robust sales growth, driven by HIV and oncology advancements, despite challenges from Veklury sales decline and Medicare reforms.",
    "url": "https://finnhub.io/api/news?id=62068bb33baf10d371048107dcc873da63df869a263fb317981ca1ac512f2bcb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739344311,
      "headline": "Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology ...",
      "id": 132766602,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/84a579dd14fa3db57968682e27407e42",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc (GILD) reports robust sales growth, driven by HIV and oncology advancements, despite challenges from Veklury sales decline and Medicare reforms.",
      "url": "https://finnhub.io/api/news?id=62068bb33baf10d371048107dcc873da63df869a263fb317981ca1ac512f2bcb"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript",
    "summary": "GILD earnings call for the period ending December 31, 2024.",
    "url": "https://finnhub.io/api/news?id=5fca3ab0669d30ab9d49bcdf6acdb3707d20e09f1689c38dc29eb778a8866db5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739330123,
      "headline": "Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript",
      "id": 132766603,
      "image": "https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD earnings call for the period ending December 31, 2024.",
      "url": "https://finnhub.io/api/news?id=5fca3ab0669d30ab9d49bcdf6acdb3707d20e09f1689c38dc29eb778a8866db5"
    }
  },
  {
    "ts": null,
    "headline": "Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=5717c7fc08cb3a57c7568e9c7bde9303f99f88137291621b97f8a4b303b1e00a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739320204,
      "headline": "Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 132766604,
      "image": "https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=5717c7fc08cb3a57c7568e9c7bde9303f99f88137291621b97f8a4b303b1e00a"
    }
  }
]